PRO131921

PRO131921 is a third-generation, humanized monoclonal antibody targeting the B-lymphocyte antigen CD20. It was engineered to enhance both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) compared to earlier anti-CD20 antibodies such as rituximab. The drug was developed for the treatment of CD20-positive B-cell malignancies, including relapsed or refractory indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia. Clinical studies demonstrated that higher drug exposure correlated with greater tumor shrinkage in patients previously treated with rituximab-containing regimens. Despite showing clinical activity, development of PRO131921 was discontinued after reaching phase 2 trials[1][2][5][6][8].

Other names

anti-CD20 monoclonal antibody PRO131921anti-CD-20 monoclonal antibody PRO131921anti-CD 20 monoclonal antibody PRO131921